USC’s Stevens Brokers Licensing Deal for Cancer Biomarkers with Abraxis Bioscience | GenomeWeb
Pharmaceutical firm Abraxis Bioscience last week said that it has exclusively licensed from the University of Southern California worldwide development and commercialization rights for diagnostic protein biomarkers related to colorectal cancer.
 
USC officials said that the licensing deal is one of the biggest the university has announced in terms of market potential since it established the Stevens Institute for Innovation earlier this year in an attempt to speed technology commercialization.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.